Keogh, R. J. http://orcid.org/0000-0001-6014-9227
Milewski, M.
Browne, K.
Egan, K.
Hennessy, M. A.
Coyne, Z.
Cowzer, D.
Linehan, A.
Hennessy, B. T.
Grogan, L.
Morris, P. G.
Breathnach, O. S.
Article History
Received: 16 December 2020
Accepted: 14 April 2021
First Online: 4 May 2021
Declarations
:
: Travel support: Patrick G. Morris, Roche, Novartis, Amgen; Honoraria: Patrick G. Morris, Astellas, Novartis, Pfizer, Teva, Nordic 2013, Bristol Meyers Squibb, Astra Zeneca, Genomic health, Roche; Consultancy or Advisory role: Patrick G. Morris, Novartis, Speaker Role: Patrick G. Morris, Teva; Research funding: Patrick G. Morris, Teva, Genomic Health.
: This study was approved by the Beaumont Hospital Institutional Review Board prior to study initiation. This study was performed in accordance with the Internal Conference on Harmonisation (ICH) for Good Clinical Practice (GCP) and the ethical principles founded in the Declaration of Helsinki.
: All patients gave written informed consent to participate in the study.